The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies

Nutrition and Diabetes

Volumn 2, Issue DECEMBER, 2012, Pages

  Armstrong, A W ^a   Harskamp, C T ^a   Armstrong, E J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidemiology; Incidence; Meta analysis; Obesity; Prevalence; Psoriasis

Indexed keywords

CASE CONTROL STUDY; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COCHRANE LIBRARY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMBASE; EPIDEMIOLOGICAL DATA; HAZARD RATIO; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; OBESITY; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; QUESTIONNAIRE; REVIEW; SELF REPORT; SYSTEMATIC REVIEW;

EID: 84877912027     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2012.26     Document Type: Review

References (43)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
2. Johnson MA, Armstrong AW. Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clin Rev Allergy Immunol; e-pub ahead of print 27 Jan 2012; DOI: 10.1007/s12016-012-8305-3.
3. Grozdev I, Kast D, Cao L, Carlson D, Pujari P, Schmotzer B et al. Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol 2012; 132: 1111-1116.
4. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55: 62-63.
5. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009; 55: 202-204.
6. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008; 158: 1134-1135.
7. Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006; 154: 83-86.
8. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
9. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol 2010; 37: 146-155.
10. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and agerelated prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
11. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509.
12. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
13. Driessen RJ, Boezeman JB, Van De Kerkhof PC, De Jong EM. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatol Treat 2009; 20: 42-47.
14. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
15. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
16. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132 (Part 1): 556-562.
17. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
18. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
19. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010; 24 885-892.
20. Shapiro J, Cohen AD, Weitzman D, Tal R, David M. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol 2012; 66: 252-258.
21. Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizuka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci 2010; 57: 143-144.
22. Warnecke C, Manousaridis I, Herr R, Terris DD, Goebeler M, Goerdt S et al. Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. Eur J Dermatol 2011; 21: 761-770.
23. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-1315.
24. Zhang C, Zhu KJ, Zheng HF, Cui Y, Zhou FS, Chen YL et al. The effect of overweight and obesity on psoriasis patients in Chinese Han population: a hospital-based study. J Eur Acad Dermatol Venereol 2011; 25: 87-91.
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
26. Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 2010; 121: 2271-2283.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
30. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13-19.
31. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 2006; 64: 355-365.
32. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.
33. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25: 805-810.
34. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287: 1706-1709.
35. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-1575.
36. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-1208.
37. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-1394.
38. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 2006; 110: 267-278.
39. Florin V, Cottencin AC, Delaporte E, Staumont-Salle D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol; e-pub ahead of print 23 May 2012; DOI: 10.1111/j.1468-3083. 2012.04571.x.
40. Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther 2011; 24: 446-451.
41. Prignano F, Ricceri F, Pescitelli L, Buggiani G, Troiano M, Zanieri F et al. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin 2009; 25: 2311-2316.
42. Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-295.
43. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344.